Surgical approach and maintenance therapy in advanced low-grade serous ovarian cancer: Insights from the French ESME database
Jean‐Sébastien Frenel(Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers), Laurence Gladieff(Institut Claudius Regaud), Renaud Sabatier(Centre National de la Recherche Scientifique), E. Martin(Institut de Cancérologie de l'Ouest), Hélène Costaz(Centre Georges François Leclerc), Cécile Loaec(Institut de Cancérologie de l'Ouest), Elise Rowinski(Centre Léon Bérard), Florence Joly(Centre François Baclesse), Emmanuel Barranger(Délégation Paris 7), L. Bosquet(UniCancer Group), Fabrice Lécuru(Université Paris Cité), Christophe Pomel(Université Clermont Auvergne), Cécile Guillemet(Centre Virchow-Villermé), Thibault De La Motte Rouge(Inserm), Patricia Pautier(Institut Gustave Roussy), Pierre Colombo(CEA Valduc), Isabelle Ray‐Coquard(European Organisation for Research and Treatment of Cancer), Catherine Guérin‐Charbonnel(Institut de Cancérologie de l'Ouest), Aude Marie Savoye(Institut Jean Godinot)
Cited by 0
Related Papers
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial
|Journal of Clinical Oncology|2005|421
BRAF Inhibition in <i>BRAF</i> <sup>V600</sup> -Mutant Gliomas: Results From the VE-BASKET Study
|Journal of Clinical Oncology|2018|330